| 1 |
28278708 | Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide. | 2017 Oct |
1 |
| 2 |
28801515 | Lenalidomide-associated arterial thrombosis in a patient with JAK2 positive atypical myeloproliferative neoplasm. | 2017 Aug 11 |
1 |
| 3 |
27330758 | Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment. | 2016 Jul |
2 |
| 4 |
27538006 | Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis. | 2016 Aug 1 |
2 |
| 5 |
25963624 | Effectiveness of lenalidomide in a patient with refractory anemia with ring sideroblasts and thrombocytosis with JAK2 (V617F) mutation. | 2015 Aug |
1 |
| 6 |
24966686 | Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy. | 2014 |
1 |
| 7 |
25189730 | Rationale for combination therapy in myelofibrosis. | 2014 Jun |
1 |
| 8 |
25469886 | Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. | 2014 |
2 |
| 9 |
23252419 | Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis. | 2013 Jul |
1 |
| 10 |
20194893 | Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. | 2010 Jul 15 |
1 |
| 11 |
20846100 | Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation. | 2010 Oct |
1 |
| 12 |
16990762 | Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. | 2006 Nov |
1 |